Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine

Efavirenz and nevirapine failure is associated with a rapid selection of resistance-associated mutations (RAMs), which may impact on etravirine or rilpivirine susceptibility. However, RAMs for rilpivirine and etravirine cannot be reported on previous resistance genotypes because these specific RAMs...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2015-02, Vol.70 (2), p.562-565
Main Authors: Gallien, S, Charreau, I, Nere, M L, Mahjoub, N, Simon, F, de Castro, N, Aboulker, J P, Molina, J M, Delaugerre, C
Format: Article
Language:English
Subjects:
Adult
Aged
Antiretroviral drugs
Antiretroviral Therapy, Highly Active
Benzoxazines - therapeutic use
Deoxyribonucleic acid
DNA
Drug resistance
Drug Resistance, Viral
Female
Genotype
Genotype & phenotype
HIV
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mutation
Nevirapine - therapeutic use
Nitriles - pharmacology
Nitriles - therapeutic use
Pyridazines - pharmacology
Pyridazines - therapeutic use
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Retreatment
Reverse Transcriptase Inhibitors - pharmacology
Reverse Transcriptase Inhibitors - therapeutic use
Rilpivirine
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efavirenz and nevirapine failure is associated with a rapid selection of resistance-associated mutations (RAMs), which may impact on etravirine or rilpivirine susceptibility. However, RAMs for rilpivirine and etravirine cannot be reported on previous resistance genotypes because these specific RAMs were not analyzed at that time. Therefore, our objective was to determine, in virologically suppressed HIV-1-infected individuals, the presence of RAMs to rilpivirine, etravirine and the combination of tenofovir/emtricitabine/rilpivirine in HIV-1 DNA from individuals previously exposed to efavirenz and/or nevirapine. The studied population included 169 treatment-experienced individuals enrolled in the ANRS 138-EASIER trial who previously failed on and/or were intolerant to efavirenz and/or nevirapine and who had plasma HIV-1 RNA
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dku395